Normal | Liver impairment | |||
---|---|---|---|---|
n (%) | Group A (n = 533) | Group B (n = 285) | Group C (n = 424) | Group D (n = 32) |
CR | 3 (0.6) | 1 (0.4) | 1 (0.2) | 0 |
PR | 59 (11.1) | 39 (13.7) | 53 (12.5) | 0 |
SD | 275 (51.6) | 141 (49.5) | 199 (46.9) | 24 (75.0) |
Progressive disease | 165 (31.0) | 82 (28.8) | 137 (32.3) | 6 (18.8) |
Not evaluable | 6 (1.1) | 10 (3.5) | 16 (3.8) | 1 (3.1) |
Unknowna | 25 (4.7) | 12 (4.2) | 18 (4.2) | 1 (3.1) |
Objective response rate (CR + PR) | 62 (11.6) | 40 (14.0) | 54 (12.7) | 0 |
95% CIb | (9.0, 14.7) | (10.2, 18.6) | (9.7, 16.3) | (0, 10.9) |
Clinical benefit rate (CR + PR + SDc) | 145 (27.2) | 70 (24.6) | 94 (22.2) | 6 (18.8) |
95% CIb | (23.5, 31.2) | (19.7, 30.0) | (18.3, 26.4) | (7.2, 36.4) |